Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
22 participants
INTERVENTIONAL
2023-05-26
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Three daratumumab dosing cohorts are planned with up to six participants in each dosing cohort with the potential to enroll an additional 4 subjects in the highest safe dose (HSD) cohort, for a total of up to 22 participants. The dosing cohorts are: 4 mg/kg, 8 mg/kg, and 16 mg/kg. Each cohort will receive intravenous (IV) administration of daratumumab according to the following schedule, for a total of 8 doses.
The primary objective is to determine the safety of daratumumab in APS defined as Dose Limiting Toxicities (DLTs) occurring during the dose escalation phase.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants
NCT03320707
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
NCT00005571
The Safety of Repurposing Daratumumab for Relapsed or Refractory Autoimmune Antibody Mediated Hemolytic Anemia
NCT05004259
Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation
NCT04088903
Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome
NCT00065390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study design is a modification of the 3 + 3 dose escalation scheme. Three daratumumab dose cohorts are planned: 4 mg/kg, 8 mg/kg, and 16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48.
Dose Escalation Phase Dose escalation will proceed according to safety criteria (Dose Limiting Toxicity, DLT) and efficacy criteria (antiphospholipid antibody negativity). An independent safety committee will review the data and approve escalation to the next dose.
The Highest Safe Dose (HSD) is the highest administered dose at which ≤ 1/6 participants experiences a DLT at or prior to week 9.
Expansion Phase Four additional participants will be enrolled and treated at the HSD weekly for 8 doses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4 mg/kg Cohort
This cohort will receive intravenous (IV) administration of 4 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
8 mg/kg Cohort
This cohort will receive intravenous (IV) administration of 8 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
16 mg/kg Cohort
This cohort will receive intravenous (IV) administration of 16 mg/kg daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Daratumumab
Participants will receive 4 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4-8 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Daratumumab
Participants will receive 4-16 mg/kg of intravenous (IV) daratumumab administered weekly for 8 doses (weeks 0 through 7). Post-treatment follow-up visits will occur at weeks 9, 12, 18, 24, 36, and 48
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The completion of the following vaccinations at least 14 days prior to Visit 0:
1. At least one dose of the most recently updated COVID-19 vaccine, and
2. At least one dose of the herpes zoster vaccination series, and
3. Current seasonal influenza vaccine, if available.
3. History of APS according to the updated 2006 Sapporo classification criteria, including at least one of the following:
a. Arterial thrombosis, except transient ischemic attack, confirmed by objective validated criteria such as imaging, or b. Venous thrombosis, except superficial thrombophlebitis, confirmed by objective validated criteria such as imaging, or c. Pregnancy morbidity, based on the updated 2006 Sapporo APS classification criteria, or d. Microvascular APS, with at least one of the following: i. Renal biopsy documentation of aPL-associated nephropathy, or ii. Lung biopsy or bronchoalveolar lavage documentation of diffuse alveolar hemorrhage (DAH), or iii. Skin biopsy documentation of livedoid vasculopathy.
4. History of triple positive aPL within the prior 5 years and at least 12 weeks prior to enrollment, including all of the following:
1. aCL IgG level \> Upper Limit of Normal (ULN), and
2. aβ2GPI IgG level \> ULN, and
3. Positive LA test.
5. Confirmation of triple positive aPL at screening, including all of the following:
1. aCL IgG level ≥ 40 GPL, and
2. aβ2GPI IgG level ≥ 40 SGU, and
3. Positive LA test.
6. Undergoing anticoagulation with warfarin or low molecular weight heparin (LMWH), if there is a history of arterial or venous thrombosis.
Exclusion Criteria
2. Inability or unwillingness to comply with study protocol.
3. Systemic autoimmune diseases other than APS, including but not limited to:
1. Systemic lupus erythematosus (SLE) meeting the EULAR/ACR classification criteria.
2. Rheumatoid arthritis meeting the ACR/EULAR classification criteria.
3. Small, medium, and large vessel vasculitis meeting ACR classification criteria.
4. Catastrophic APS classification within the prior 90 days.
5. Acute arterial or venous thrombosis within the prior 30 days.
6. Use of the following medications:
1. Any prior treatment with CD38 targeting monoclonal antibodies, including daratumumab or isatuximab-irfc.
2. The following within the prior 30 days:
i. Corticosteroids \> 10 mg/day prednisone or equivalent. ii. Direct oral anticoagulants (DOACs). iii. Live attenuated vaccines. iv. IVIG or other supplemental immunoglobulin. c. Azathioprine, methotrexate, mycophenolate mofetil, mycophenolate sodium, lefluonomide, or calcineurin inhibitors within the prior 90 days.
d. Cyclophosphamide within the prior 90 days. e. Immunomodulatory or immunosuppressive biologic agents, including belimumab, within the prior 90 days or 5 half-lives, whichever is greater.
f. Investigational agents within the prior 90 days or 5 half-lives, whichever is greater, except for COVID-19 vaccines and medications for prevention or treatment of COVID-19 per FDA Emergency Use Authorization (EUA).
g. Biologic B cell depleting agents including rituximab with any of the following: i. Treatment within the prior 180 days, or ii. CD19+ absolute count \< 40/ μl, or iii. Serum IgG \<500 mg/dL.
7. Plasma exchange within the prior 90 days.
8. Hemodialysis within the prior 90 days.
9. Major surgical procedure within the prior 60 days.
10. Known allergy, hypersensitivity, or intolerance to boron, malitol, sorbitol, corticosteroids, monoclonal antibodies including daratumumab, human proteins, or their excipients.
11. Allergy, intolerance, or contraindication to acyclovir, valacyclovir, and famciclovir.
12. Active or chronic infection, including the following:
1. Active bacterial, viral, fungal, or opportunistic infection.
2. Chronic infection requiring suppressive antibiotic treatment.
3. Intravenous antibiotics or hospitalization for infection within the prior 30 days.
4. Evidence of current or prior Mycobacterium tuberculosis infection.
5. Human immunodeficiency virus (HIV).
6. Current or prior infection with hepatitis B virus (HBV).
7. Current or prior infection with hepatitis C virus (HCV), except adequately treated HCV with sustained virologic response ≥ 12 weeks.
8. History of recurrent herpes zoster, or history of herpes zoster ophthalmicus, disseminated herpes zoster, or disseminated herpes simplex.
13. The following laboratory abnormalities:
ITN093AI: DARE-APS Version 3.0 September 12, 2023 Daratumumab in Primary Antiphospholipid Syndrome
1. Absolute neutrophil count \< 1500/mm3.
2. Platelets \< 100,000/mm3.
3. Hemoglobin (Hgb) \< 10 g/dL.
4. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase \> 2x the Upper Limit of Normal (ULN).
5. Total bilirubin \> 2x ULN, except in the case of congenital bilirubinemia then direct bilirubin \> 2x ULN.
6. eGFR \< 45 ml/min/1.73 m2.
14. History of primary immunodeficiency.
15. History of solid organ or hematopoietic stem cell transplantation.
16. Comorbidities requiring systemic corticosteroid therapy, including those which have required three or more courses of systemic corticosteroids within the 12 months prior to Visit 0.
17. Any of the following conditions with FEV1 \< 70% predicted within the prior 90 days:
1. Asthma.
2. Chronic obstructive pulmonary disease (COPD).
3. DAH.
18. Pulmonary hypertension.
19. Adrenal insufficiency.
20. Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 8.0%.
21. Concomitant malignancy or history of malignancy, except adequately treated or excised nonmetastatic squamous cell carcinoma, basal cell skin carcinoma, or cervical carcinoma in situ.
22. Clinically significant cardiac disease, including but not limited to:
1. Myocardial infarction within the prior 6 months, or
2. Unstable or uncontrolled disease or condition related to or affecting cardiac function, including but not limited to:
i. Unstable angina, or ii. Congestive heart failure, New York Heart Association Class II-IV, or iii. Uncontrolled cardiac arrhythmia.
23. Current diagnosed mental illness or current diagnosed or self-reported drug or alcohol abuse which, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
24. Severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease.
25. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements, or may impact the quality or interpretation of the data obtained from the study.
26. Lack of peripheral venous access.
27. Pregnancy, or planning a pregnancy during the 48 week study duration.
28. Breast-feeding.
29. Unwillingness to use medically acceptable non-prothrombotic contraception if of reproductive potential and engaging in sexual activity that could lead to pregnancy.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Immune Tolerance Network (ITN)
NETWORK
PPD Development, LP
INDUSTRY
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Doruk Erkan, M.D., M.P.H.
Role: STUDY_CHAIR
Hospital for Special Surgery, New York: Division of Rheumatology
Jason Knight, M.D., Ph.D.
Role: STUDY_CHAIR
University of Michigan Health System: Department of Internal Medicine, Division of Rheumatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins University
Baltimore, Maryland, United States
University of Michigan
Ann Arbor, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Northwell Health
Great Neck, New York, United States
NYU Langone
New York, New York, United States
Hospital for Special Surgery
New York, New York, United States
Weill Cornell
New York, New York, United States
Duke University
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Immune Tolerance Network
National Institute of Allergy and Infectious Diseases
Division of Allergy, Immunology, and Transplantation
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIT ITN093AI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.